Author Archives: Marta Figueiredo PhD

Risk of Severe COVID-19 Not Raised by Immunosuppressive DMTs

Exposure to multiple sclerosis (MS) disease-modifying therapies (DMTs), and particularly immunosuppressive DMTs, does not increase the risk of developing a severe form of COVID-19, or of dying from the disease, when adjusting for known risk factors, an Austrian registry-based study found. These findings add to data showing no…

Oral CKD-506 Lessens Symptoms, Demyelination in MS Mouse Model

Chong Kun Dang (CKD) Pharmaceutical’s experimental oral therapy CKD-506 suppressed inflammation, myelin loss (demyelination), and lessened symptoms in a mouse model of multiple sclerosis (MS), a study reported. Notably, the therapy resulted in benefits generally comparable to those of Gilenya (fingolimod) in these mice. But it also…

Targeting Ion Channel Piezo1 in T-cells Eased MS in Mice

Removing an ion channel called Piezo1 from immune T-cells lessened disease severity in a mouse model of multiple sclerosis (MS), a study showed. Notably, these beneficial effects were associated with an expansion of regulatory T-cells (Tregs) — a type of immune cell that typically dampens immune and inflammatory responses —…

MS-related Fatigue Identified as Main Factor Affecting Work Ability

Fatigue, whether alone or in combination with depression or anxiety, is the main influencing factor of self-reported working ability among people with relapsing-remitting multiple sclerosis (RRMS) and mild disability, according to a study in the Netherlands. Notably, contrary to the researchers’ expectations, personality traits were found to have…

Kesimpta for RRMS Now Available in Scotland at Low or No Cost

Adults in Scotland with active relapsing-remitting multiple sclerosis (RRMS) will now have access at low or no cost to Kesimpta (ofatumumab), the first self-administered, at-home B-cell-targeting therapy for people with the neurodegenerative disease. The Scottish Medicines Consortium (SMC) recommended that the Novartis therapy be available through the…

MS-related Fatigue Strongly Affects Youngsters’ Functioning

Multiple sclerosis and its associated fatigue negatively affect school performance, mental health, and physical and social functioning in children and adolescents with the disease, according to a review study. Pediatric-onset multiple sclerosis (POMS) also was associated with negative effects on social functioning, mental health, and quality of life in…

Robotic Exoskeleton Intervention Improves Motor, Cognitive Function

Four weeks of robotic exoskeleton-assisted exercise rehabilitation, called REAER, worked better than conventional gait training in improving mobility and cognitive function in multiple sclerosis (MS) patients with substantial walking difficulties, according to a small trial. A robotic exoskeleton consists of an externally worn device that encases a user’s hips, back,…

Qynapse Announces Research Collaborations for World MS Day

Qynapse, a company that combines artificial intelligence with neuroimaging technology, is reaffirming its commitment to help advance multiple sclerosis (MS) research and care in recognition of World MS Day. World MS Day is officially celebrated on May 30, with global events and activities designed to raise disease awareness.

At-home Brain Stimulation Program Now Available

New York University (NYU) Langone Health has launched an at-home, therapeutic program of transcranial direct current stimulation (tDCS) — a type of non-invasive brain stimulation — to reduce cognitive, motor, speech, or mood symptoms associated with multiple sclerosis (MS) and other brain disorders. A first of its kind, the…

Mayzent, Zeposia May Lose Ground in Canada, Report Finds

Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently approved in Canada for treating multiple sclerosis (MS), showed strong launches in the country, according to the latest Spherix Global Insights’ report. However, due to several internal and external factors, sustained relevance of these…

MS May Not Affect Breast Cancer Survival, Study Suggests

Women with multiple sclerosis (MS) diagnosed with breast cancer are not at a higher risk of dying from cancer than women without the neurodegenerative disorder, according to a Canadian population-based study. However, 10 years after their breast cancer diagnosis, women with MS were 28% more likely to die from any…

Overall Cost of DMTs Stable 2018–2020, Study Finds

The overall cost of disease-modifying therapies for multiple sclerosis (MS) in the U.S. remained stable from 2018 to 2020, according to pharmacy and medical claims data from Prime Therapeutics’ insured members. This stabilization derived from a balance between a reduction in Copaxone (glatiramer acetate injection) use due…

Kesimpta Approved in EU as At-home Injectable Therapy for Relapsing MS

The European Commission has approved Novartis’ Kesimpta (ofatumumab) as the first self-administered, at-home B-cell-targeting therapy for adults with relapsing forms of multiple sclerosis (MS) and active disease. Active disease in these forms, which include clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS),…

NMSS Partnership Targets Autoimmune Disease Research

The National Multiple Sclerosis Society has joined forces with the diabetes-focused JDRF and the Lupus Research Alliance to fund research looking at common underlying mechanisms of autoimmune disease. Called “Decoding Immune-Mediated Diseases – Novel Approaches for Therapeutic Insights,” the new joint grant program is meant to stimulate…

The Multiple Sclerosis Podcast


Survey Icon

Video